✦ LIBER ✦

Erosive osteoarthritis during treatment with bevacizumab and paclitaxel in a patient with recurrent papillary serous carcinoma of the ovary

✍ Scribed by A. JAISHUEN; J.P. BERRIOS-RIVERA; N. SIRISABYA; H.G. ZHENG; Y. LI; J.J. KAVANAGH

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Prognostic factors for recurrence after

✍ Uzan, C.; Muller, E.; Kane, A.; Rey, A.; Gouy, S.; Bendiffallah, S.; Duvillard, 📂 Article 📅 2014 🏛 Oxford University Press 🌐 English ⚖ 176 KB

A meta-analysis of bevacizumab alone and

✍ Zhang, Guobin; Huang, Shengyue; Wang, Zhongcheng 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 160 KB

Phase II trial of imatinib mesylate in p

✍ Ignacio Romero Noguera; Charlotte C. Sun; Russell R. Broaddus; Donna Branham; Ch 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 168 KB

Erlotinib and bevacizumab in patients wi

✍ Ezra EW Cohen; Darren W Davis; Theodore G Karrison; Tanguy Y Seiwert; Stuart J W 📂 Article 📅 2009 🏛 The Lancet 🌐 English ⚖ 442 KB

AOSOP3 Combination of bevacizumab and er

✍ T. Yau; H. Wong; P. Chan; T.J. Yao; T.T. Cheung; S.T. Fan; R.T. Poon 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 151 KB

A phase II clinical trial of diaziquone

✍ Robert E. Slayton; John A. Blessing; Mark Rettenmaier; Harrison Ball 📂 Article 📅 1989 🏛 Springer US 🌐 English ⚖ 251 KB